தொழில்துறை ஆராய்ச்சி உதவி ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Locally created app matches drivers with underutilized parking spots
winnipegfreepress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from winnipegfreepress.com Daily Mail and Mail on Sunday newspapers.
GTAA and Switch Health introduce Covid-19 testing services
airport-technology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from airport-technology.com Daily Mail and Mail on Sunday newspapers.
CALGARY A Calgary-based drug maker successfully posted promising phase one trial results for its own COVID-19 vaccine, but the company’s future endeavours in Canada remain a question mark without federal funding for manufacturing. Providence Therapeutics released results Wednesday from 60 participants aged 18 to 64 that participated in the trial, which show “strong virus neutralization capability,” with no serious side effects reported. Participants received either a placebo or the PTX-COVID19-B vaccine made by Providence in one of three dose sizes. After 28 days, participants given any of the vaccine sizes showed COVID-19 antibodies, while all doses showed 100 per cent COVID-19 “blocking activity” after 42 days.
Article content
The federal government must provide significantly more support to a select few high-growth firms if it wants to foster more globally competitive business giants, according to an unpublished report by former Ryerson University president Sheldon Levy.
In December 2018, Small Business Minister Mary Ng appointed Levy to advise her on how to help small- and medium-sized firms scale up, a key priority for the Liberal government in its first term. Innovation-economy executives and industry associations have long awaited the results of his work.
We apologize, but this video has failed to load.
Try refreshing your browser. Ottawa should offer more support to help select few high-potential firms scale: Levy report Back to video
vimarsana © 2020. All Rights Reserved.